Breast cancer speci®c gene 1 (BCSG1), also referred as synuclein g, is the third member of a neuronal protein family synuclein. BCSG1 is not expressed in normal breast tissues but highly expressed in advanced in®ltrat-ing breast carcinomas. When over expressed, BCSG1 signi®cantly stimulates breast cancer metastasis. To elucidate the molecular mechanisms underlying the abnormal transcription of BCSG1 in breast cancer cells, in this study, we isolated a 2195 base pair fragment of human BCSG1 gene. This fragment includes 1 kb 5'-anking region, exon 1, and intron 1. By analysing the promoter activity and the methylation status of the exon 1 region, we show that (1) Intron 1 plays critical roles in the control of BCSG1 gene transcription through cisregulatory sequences that aect BCSG1 transcription in cell type-speci®c and cell type-nonspeci®c manners. (2) The activator protein-1 (AP-1) is functionally involved in BCSG1 transcription in breast cancer cells through its binding to an AP-1 motif located in the intron 1. (3) The exon 1 region of BCSG1 gene contains a CpG island that is unmethylated in BCSG1-positive SKBR-3 and T47D cells but densely methylated in BCSG1-negative MCF-7 cells. (4) Treating MCF-7 cells with a demethylating agent 5-Aza-2'-deoxycytidine speci®cally activated BCSG1 transcription. Thus, our results suggest that while the cellular content of transcription activators and repressors that interact with the cis-regulatory sequences present in the intron 1 contribute prominently to the tissue-speci®c expression of BCSG1, demethylation of exon 1 is an important factor responsible for the aberrant expression of BCSG1 in breast carcinomas. Oncogene (2001) 20, 5173 ± 5185.
Introduction
Breast cancer speci®c gene 1 (BCSG1) was originally identi®ed through dierential cDNA sequencing and was isolated from a human breast tumor cDNA library (Ji et al., 1997) . The BCSG1 gene is transcribed into a 1 kb mRNA, and encodes a 127-amino acid polypeptide. Comparison of the predicted amino acid sequence with genetic databases reveals that BCSG1 is highly homologous to a family of neuronal cytosolic proteins, namely synucleins that are mainly expressed in brain and are localized to presynaptic terminals (Ueda et al., 1993; Jakes et al., 1994; Xia et al., 1996) . BCSG1 shares 54 and 56% amino acid sequence identity with synuclein a and synuclein b respectively. Subsequent to the isolation of BCSG1, synuclein g (Lavedan et al., 1998) and persyn (Ninkina et al., 1998) were independently cloned from a brain genomic library and a brain cDNA library. The sequences of these two brain proteins were found to be nearly identical to BCSG1. The ®ve nucleotide dierences found between BCSG1 and the sequences reported for synuclein g and persyn are the results of natural nucleotide polymorphisms (Ninkina et al., 1998) . Thus, BCSG1 is now also named synuclein g or persyn and is considered to be the third member of the synuclein family.
Being identi®ed as a breast cancer speci®c gene, BCSG1 mRNA was detected in neoplastic breast epithelial cells but not in normal mammary epithelial cells (Ji et al., 1997) . In situ hybridization analysis has demonstrated a stage-speci®c expression pattern of BCSG1 mRNA varying from virtually no detectable expression in normal or benign breast tissue to low level and partial expression in low grade breast carcinoma in situ to high expression in advanced in®ltrating carcinomas. Immunohistochemical studies to examine BCSG1 protein expression showed a similar pattern in that it was not detected in normal breast tissues, but was detected in a high percentage of Stage III/IV breast ductal carcinomas (Bruening et al., 2000) . These ®ndings suggest that BCSG1 may play a positive role in breast cancer disease progression. This speculation is strongly supported by our recent study showing that over expression of BCSG1 in breast cancer cell line MDA-MB 435 cells led to a signi®cant increase in motility and invasiveness in cell culture and a profound augmentation of metastasis in nude mice (Jia et al., 1999) . In addition to stimulating breast cancer cell invasion and metastasis, BCSG1 may also be involved in cell proliferation, as we have shown that exogenous expression of BCSG1 in MCF-7 cells signi®cantly stimulated the growth of MCF-7 cells under anchorage-dependent and anchorage-independent conditions (Liu et al., 2000) .
Mutations in synuclein a have been detected in several cases of familial Parkinson's diseases (Polymeropoulos et al., 1997) . Analogous to synuclein a, mutations of BCSG1 could be linked to the development of breast carcinomas. However, after analysis of a number of breast tumors and breast cancer cell lines, Ninkina et al. (1998) has reported that the malignant phenotype is correlated with the high level expression of wild-type BCSG1 protein. Moreover, in addition to the absence of mutation, BCSG1 gene ampli®cation was also not detected in breast tumors.
Our previous study has shown that the expression of BCSG1 in H3922 breast cancer cells was down regulated by the growth-inhibitory cytokine oncostatin M (OM) (Liu et al., 2000) . H3922 is a breast cancer cell line derived from an in®ltrating breast carcinoma (Liu et al., 1997a) . This cell line expresses high level of BCSG1 (Ji et al., 1997) . Treatment of H3922 cells with OM for 2 days totally inhibited the expressions of BCSG1 mRNA and protein. Nuclear run-on assays demonstrated that suppression of BCSG1 mRNA expression by OM occurred at the level of transcription. In addition to OM, BCSG1 mRNA expression was also regulated by EGF and TGF b in these cells.
Based on the accumulated evidence from dierent lines of investigations we hypothesized that the aberrant expression of BCSG1 in breast carcinomas is caused by transcriptional activation of the BCSG1 gene, and its transcription in breast cancer cells is subject to regulation by cellular factors that aect cell growth, dierentiation, and, likely, metastasis.
In order to elucidate the molecular mechanisms that convert BCSG1 from a silent gene in normal breast tissue to an actively transcribed gene in breast tumor, and to identify upstream regulators of BCSG1 transcription in neoplastic mammary epithelial cells, in this report we cloned the 5' promoter region and the ®rst intron of the BCSG1 gene. By analysis of the BCSG1 promoter activities in a panel of cell lines, we demonstrate that the transcription of BCSG1 in breast cancer cells is controlled by DNA methylationdependent and independent mechanisms.
Results
Isolation of the 5'-flanking region, exon 1, and intron 1 of the BCSG1 gene To clone the BCSG1 gene 5'-¯anking region we performed a BLAST search of the GenBank TM /EBI Data Bank (htgs) by using the 5' untranscribed sequence (500 bp) of the published persyn genomic sequence. The search identi®ed the genomic clone RP11-411A19 that contains the published genomic sequence of persyn. Based upon the working draft of this clone, restriction enzymes SacI and BamHI were chosen to digest the genomic clone. Southern blot using a 32 P-labeled probe of 60 base single stranded oligonucleotide corresponding to the persyn genomic sequence (141 to 200) was conducted and a single band of 1.7 kb was identi®ed. This fragment was cloned in correct orientation into the pBluscript KS+ vector (pBS-BCSG1759). Because the 1.7 kb genomic fragment contains only the 5' portion of intron 1, we subsequently isolated the 3' portion of intron 1 by PCR reaction using the clone RP11-411A19 as the template and ligated in frame into pBS-BCSG1759. The resulting plasmid pBS-BCSG2195 contains a 2195 bp genomic fragment of the BCSG1 gene. Using overlapping internal primers (Table 1) , the insert of pBS-BCSG2195 was completely sequenced and the results showed a 100% homology to the sequence of the genomic clone RP11-411A19. The proximal 1544 base pairs correspond to the published persyn genomic sequence 1 ± 1544, thereby establishing its authenticity. Thus, the isolated 2195 bp fragment of BCSG1 gene includes 1 kb 5'-¯anking region, exon 1, and the complete intron 1. The sequence of this genomic fragment is shown in Figure 1 .
Determination of the 5'-end of the exon 1
To determine the transcription initiation site of the BCSG1 gene, using a 32 P-end-labeled antisense primer BCSG-PR2, derived from the BCSG1 ®rst exon (+9 to 715, relative to the adenosine nucleotide of the ATG translation start codon), 5' extension assay was conducted with mRNAs isolated from SKBR-3 and T47D breast cancer cells that have been previously shown to express BCSG1 mRNA at high levels (Ji et al., 1997) . The BCSG-PR2 primer generated two major bands of 170 and 178 bases with equal intensities from the reaction mixtures that contained mRNA of SKBR-3 or T47D but not from the control sample without mRNA (Figure 2 ). This result indicates that the transcription of BCSG1 is initiated at position 7169 and 7161, resulting in two slightly dierent sizes of exon 1 of 290 bp and 282 bp.
Sequence analysis of the BCSG1 promoter and 3' flanking region down stream of the transcription initiation sites Figure 1 shows the sequence of the isolated BCSG1 genomic fragment. This genomic sequence (71260 to +935) includes the 5'-¯anking promoter region (71260 to 7170), exon 1 (7169 to +121), and the ®rst intron (+122 to +935). The adenosine nucleotide of the ATG translation start codon is labeled as +1. The putative regulatory cis-acting elements including three AP-1 binding sites located in the promoter region and the intron 1, were identi®ed by using MatInspector V2.2. The DNA sequence proximal to the transcription Regulation of BCSG1 transcription by DNA methylation and intronic sequences A Lu et al initiation sites does not contain a consensus TATA box, instead, a GC-rich region (7200 to 7176), consisting of three potential Sp1 binding sites, is located immediately upstream of the 5' transcription start site. In addition, we found a Cap signal-like sequence between the two transcription initiation sites (7167 to 7160). The presence of a CpG island in the promoter region of BCSG1 was examined by the Webgene program and the analysis indicates that the region from 7169 to +73, comprising most of the exon 1, is a CpG island as de®ned by Gardiner-Garden and Frommer (1987) .
Regulatory sequences including cell type-specific and cell type-nonspecific are located in intron 1
The diagram of BCSG1 promoter-luciferase reporters is shown in Figure 3 . In order to examine the tissuespeci®c transactivation of the BCSG1 promoter constructs, four cell lines were chosen for transient transfection based upon their expression status of the endogenous BCSG1 gene. Western blot analyses ( Figure  4a ) demonstrate that BCSG1 protein was expressed in SKBR-3 and T47D cells, but not in MCF-7 breast cancer cells, which con®rmed our previous studies by Northern blot (Ji et al., 1997) . HepG2 cells, derived from a human hepatoma and unrelated to breast cancer cells, were included as a negative control.
To examine the BCSG1 promoter activity in dierent cell lines, ®rst, the reporters BCSG-1249 and BCSG-1759 were transiently transfected into cells along with the renilla luciferase expression vector pRL-SV40 and the dual luciferase activities were measured. Figure 4b illustrates summarized results of four separate transfections. BCSG-1249 that contains only the 5'-¯anking region of the BCSG1 gene (71260 to 712) produced similar levels of luciferase activities in all four cell lines. In contrast, the promoter construct BCSG-1759 that contains the 5'¯anking region and a portion of the ®rst intron (71260 to +499) was dierentially activated. The promoter activities of BCSG-1759 were notably increased in SKBR-3 and T47D cells, but signi®cantly decreased in HepG2 cells. Figure 4c further shows a dose-dependent dierential activation of BCSG-1249 versus BCSG-1759 in HepG2 cells. These results suggest that the regulatory sequences involved in tissue-speci®c expression of BCSG1 may be located in intron 1. In MCF-7 cells, the promoter activities of BCSG-1249 and BCSG-1759 were not statistically dierent (P=0.1). Thus, it is possible that dierent expression levels of BCSG1 gene among breast cancer cells may be controlled by some other mechanisms. To further examine the roles of intron 1 in regulation of BCSG1 transcription, we transfected additional luciferase reporters that contain the same 5' sequence but dierent lengths of 3' down stream sequences. Figure 5 shows summarized results of four separate transfection assays. In comparison to BCSG-1249, inclusion of 3' sequences from 713 to +116 (BCSG-1377) or to +292 (BCSG-1553) did not signi®cantly change the promoter activities in any cell lines. However, including further 3' sequence of intron 1 to +499 (BCSG-1759) slightly and consistently increased the promoter activities in SKBR-3 and T47D cells but signi®cantly decreased the promoter activity in HepG2 cells. These data further narrowed down a regulatory sequence that suppresses the BCSG1 transcription in HepG2 cells to a region within intron 1 from +293 to +499. We designated this negative regulatory sequence as repressive element 1 (RE1).
Intriguingly, the promoter activities of BCSG-2195 were strikingly higher than BCSG-1759 in SKBR-3, T47D, and HepG2 cells, thereby suggesting that the 3' region of intron 1 from +500 to +935 contains a positive regulatory sequence(s) that activates BCSG1 transcription without cell type-speci®city.
Localization of the positive regulatory sequence to an AP-1 motif
To identify this positive cis-acting element, additional 3' intron 1 deletion constructs were made and examined in transfection assays. Compared with BCSG-2195, the vector BCSG-1967 with deletion of the 3' end of intron 1 from +707 to +935 had a higher promoter activity, suggesting that the 3' end of intron 1 may contain a repressive element to whom we designated as repressive element 2 (RE2). However, further deletion to +599 (BCSG-1864) markedly decreased the BCSG1 promoter activity to the level of BCSG-1759 ( Figure 6a ). These data clearly localized the activating sequence to the region +599 to +706. Interestingly this region contains a perfect AP-1 element located at +612 (TGACTCA). Figure 6b shows the results of EMSA using a 32 P-labeled double- (lane 7), suggesting that the AP-1 DNA complex is mainly composed of the cjun homodimer and the c-jun/c-fos heterodimer may represent a minor component. These results demonstrated the speci®c interaction of AP-1 with this sequence motif. The AP-1 DNA protein complex was also detected from nuclear extracts of another three cell lines (data not shown). We next mutated this AP-1 binding site on BCSG-1967 to examine the functional involvement of AP-1 in BCSG1 transcription. Figure  6c shows that mutation of the AP-1 binding site at +612 in the intron 1 profoundly decreased BCSG1 promoter activity in all the four cell lines. Thus, these results together identi®ed AP-1 as a transactivator for BCSG1 transcription through its interaction with the AP-1 element located in the intron 1.
Sequences required for the basal transcriptional activity of the BCSG1 promoter
The 5' promoter region 71260 to 712 appears to provide basal minimum transcriptional activities with- out cell-type speci®city. To identify functional cisacting elements that are responsible for the basal BCSG1 gene transcription, 5' deletion mutants of BCSG-1249 were constructed and tested in transfection assays. Deletion of the 5' sequence of BCSG1 promoter from 71260 to 7308 did not signi®cantly diminish the basal promoter activity in any cell lines (data not shown). Thus, the minimal sequence required for the basal activity of the BCSG1 promoter resides within 296 bp (7307 to 712) where the GC-rich region is located (7202 to 7173). Figure 7a demonstrated the speci®c interaction of Sp1, but not other Sp family members, with the 32 P-labeled double-stranded oligonucleotide probe BCSG-Sp1, corresponding to the GCrich region of BCSG1 promoter.
To determine the function of Sp1 in mediating the BCSG1 basal promoter activity, the Sp1 binding sites were deleted from BCSG-1759 and the mutated reporter BCSG-1759-Sp1 del along with BCSG-1759 wild-type vector were transfected into SKBR-3 and HepG2 cells. Figure 7b shows that deletion of the GCrich region drastically reduced the BCSG1 promoter activities to the background levels in both SKBR-3 and HepG2 cells, thereby demonstrating the critical role of Sp1 in the basal transcription of the BCSG1 gene.
Demethylation of BCSG1 exon 1 in SKBR-3 and T47D cells
The results from promoter analysis described above raised a critical question as to why there are moderate levels of BCSG1 promoter activities in MCF-7 and HepG2 cells while the endogenous gene is not expressed. Clearly, there are additional mechanisms that control endogenous BCSG1 transcription that do not apply to the promoter reporters. Sequence analysis shows that the region of BCSG1 gene 7169 to +73, comprising most of exon 1, is a CpG island. This region contains a 63% C+G content and 14 CpG sites.
To determine a correlation between DNA methylation of the CpG island in exon 1 with the expression of endogenous BCSG1 mRNA, we examined the in vivo methylation status of exon 1 using the method of genomic bisul®te sequencing. Genomic DNA isolated from SKBR-3, T47D, MCF-7, and HepG2 cells were treated with sodium bisul®te, and the modi®ed DNAs were ampli®ed with the primer BCSG-S1F and BCSG-S1R. This primer set speci®cally ampli®ed the modi®ed sense strand of BCSG1 gene, covering the region 7342 to +260. The results obtained from all four cell lines are summarized in Table 2 . These data show that the 14 CpG sites within CpG island and 1 CpG site outside the 3' border of the CpG island were totally unmethylated in SKBR-3 and T47D cells, but were densely and heterogeneously methylated in MCF-7 cells. The CpG sites 7 and 11 ± 15 were 100% 5) , or in the presence of antibodies (lanes 6 ± 8). The reaction mixtures were loaded onto a 6% polyacrylamide gel and run in TGE buer at 180 V for 2.5 h at 48C. (c) Mutation analysis of AP-1 motif methylated among the eight clones, whereas sites 1 ± 10 were partially methylated. Interestingly, HepG2 cells showed a similar methylation pattern but more homogeneous. In HepG2 cells, the CpG sites, 2, 5, 7, and 10 ± 15 were totally methylated, whereas the sites 1, 3, 4, 6, 8, and 9 were completely unmethylated among the six clones. These data suggest that the CpG sites 2, 5, 7, and 10 ± 15 are the hot spots for DNA methylation on BCSG1 gene. The bisul®te sequencing results demonstrate that the endogenous BCSG1 mRNA expression correlates with the methylation of CpG island in that it is densely methylated in BCSG1-negative and totally unmethylated in BCSG1-positive breast cancer cells.
Detection of BCSG1 mRNA in MCF-7 and HepG2 cells after treatment of 5-Aza-2'-deoxycytidine
To further explore the role of promoter DNA methylation in the control of BCSG1 transcription, MCF-7 cells were treated with a demethylating agent 5-Aza-2'-deoxycytidine (5-aza-C) at concentrations of 1 mM and 5 mM for a period of 1 to 5 days. Total RNAs were isolated and RT ± PCR with speci®c primers to BCSG1 cDNA or GAPDH cDNA was conducted. In this assay, the total RNA isolated from SKBR-3 cells was used as a positive control. As shown in the middle panel of Figure 8a , the 337 bp fragment of BCSG1 was not seen in untreated MCF-7 cells, but this band appeared in the 5-aza-C treated samples and its intensity was increased by the treatment in a doseand time-dependent manner. Since several DNA fragments of dierent sizes were ampli®ed by the BCSG1 primers, Southern blotting with the 32 P-labeled BCSG1 cDNA probe was performed to determine whether these fragments were also derived from the BCSG1 mRNA. The result shown in the top panel indicates that only the 337 bp fragment was hybridized to the cDNA probe, demonstrating that the other bands were nonspeci®c. The bottom panel shows the products of GAPDH that were evenly ampli®ed from all the samples, illustrating that the expression of GAPDH mRNA was not altered by the 5-aza-C treatment. Similar experiments were conducted with total RNAs isolated from untreated or 5-aza-C treated HepG2 cells. Figure 8b shows that treating HepG2 cells with the demethylating agent activated BCSG1 gene expression as well. However, in both cell lines, 5-aza-C treatment did not reactivate BCSG1 transcription to the same level observed in SKBR-3 cells.
In order to determine that reactivation of BCSG1 expression in MCF-7 and HepG2 cells by 5-aza-C were results of the demethylation of the exon 1, we isolated DNA from 5-aza-C treated cells and performed bisul®te sequencing. The results shown in Table 3 demonstrated that all 15 CpG sites of exon 1 were completely demethylated in HepG2 cells after 6 days treatment of 5-aza-C at 5 mM concentration. Among six MCF-7 clones, four clones were completely demethylated with the exception of one CpG site, one clone were partially demethylated and one clone remained methylated. These data showed demethylation of exon 1 of BCSG1 gene by 5-aza-C treatment in all of the HepG2 cells and a high proportion of MCF-7 cells.
Finally, we were interested to know whether 5-aza-C treatment could aect the expression of transcription activators or repressors that interact with the promoter and the intron 1 region. To test this, MCF-7 and HepG2 cells were untreated or treated with 5-aza-C (5 mM) for 6 days and then transfected with BCSG1 promoter constructs. Figure 9 shows that the normalized luciferase activities of BCSG-1249 and BCSG-1759 were not altered by 5-aza-C treatment. The promoter activities of BCSG-1759 were still lower than BCSG-1249 in untreated and treated HepG2 cells, indicating percentage methylation based on 6 ± 8 independent clones. Nd, not determined that the repressive function of RE1 was not aected by the demethylating agent. Analysis of other promoter constructs (BCSG-1967 and BCSG-2195) showed similar results (data not shown).
Discussion
In this study, we have cloned a 2195 bp fragment of the BCSG1 gene that includes the 1 kb 5' promoter region, exon 1, and intron 1. Analysis of luciferase activities of reporter constructs that contain dierent 5' and 3' deletions of this fragment revealed two important features of BCSG1 gene transcription. First, the 5' promoter region is likely not involved in the cell type-speci®c transcription of BCSG1. Under normal culture conditions without extra cellular stimuli, the promoter construct BCSG-1249 was moderately active in both BCSG1-postive (SKBR-3, T47D) and BCSG1-negative (MCF-7, HepG2) cell lines. The function of this promoter region appears to provide the basal transcriptional activity without cell type-speci®city. We have identi®ed a GC-rich sequence (7202 to 7173), located immediately upstream of the transcription initiation sites, as an important functional element for the basal promoter activity. We show that transcription factor Sp1 speci®cally bind to this region. Deletion of this GC-rich region in the construct BCSG-1759 greatly reduced the promoter activity in both SKBR-3 and HepG2 cells. These results suggest that in the absence of an identi®able TATA box, this GC-rich region serves as a critical promoter element to interact with the basal transcriptional machinery. The second important and unique feature of BCSG1 transcription is that intron 1 plays a critical role in the control of gene transcription. We have identi®ed regions within intron 1 that in¯uence BCSG1 promoter activity in cell type-speci®c and cell type-nonspeci®c manners. We show that a 203 bp region of the intron 1 from +293 to +499 contains a regulatory sequence (RE1) that suppresses the basal transcriptional activity mediated by the 5' promoter sequence only in HepG2 cells but not in breast cancer cells. We speculate that RE1 binding protein(s) may express in a tissue speci®c manner such as expressed in HepG2 cells, but not in breast cancer cells, or normal mammary epithelial cells. Identi®cation of the RE1 element and characterization of the RE1 binding protein(s) will provide a molecular basis for the tissue-speci®c repression of BCSG1 transcription through this repressive element. Experiments to locate and characterize the RE1 within this intron 1 region are being conducted.
In contrast to RE1, the 3' intron 1 region from +599 to +707 contains a positive regulatory sequence that markedly increases BCSG1 promoter activity in all the cell lines. We have localized this regulatory element to the AP-1 binding site at +612. Deletion or mutation of the AP-1 motif profoundly reduced the BCSG1 promoter activity. Gel shift assays showed that the AP-1 DNA binding complex can be supershifted by anti-cjun antibody. Addition of anti-c-fos antibody alone to the reaction mixture did not produce a supershifted band, whereas addition of anti-c-jun and anti-c-fos together produced one additional supershift band of low intensity as compared to anti-c-jun only. It is possible that the antibody recognition domain of c-fos Figure 8 RT ± PCR analyses of BCSG1 mRNA in 5-aza-C treated MCF-7 and HepG2 cells. MCF-7 (a) or HepG2 (b) cells were treated with 5-aza-C at the indicated concentrations for a period of 5 ± 6 days. At the end of treatment, total RNA was isolated from all the samples simultaneously and 1 mg of total RNA was used for the RT ± PCR reaction to detect BCSG1 mRNA or GAPDH mRNA. The RT ± PCR products were separated on a 1.5% agarose gel and stained with ethidium bromide. Southern blot analysis using a 32 P-labeled BCSG1 cDNA probe was performed to con®rm the expression of BCSG1 mRNA in 5-aza-C treated cells. Total RNA isolated from SKBR-3 cells was used as a positive control Figure 9 Analyses of BCSG1 promoter activities in untreated and 5-aza-C treated cells. MCF-7 and HepG2 cells were cultured in medium without or with 5-aza-C (5 mM) for 6 days and the medium and drug were replaced every 24 h. Then cells were trypsinized and cultured in medium with or without 5-aza-C in 24 well culture plates for transfection. During the transfection, cells were continuously treated with the drug. The promoter activities were analysed as described in Figure 4b present in the AP-1 DNA complex was not properly exposed to the anti-c-fos antibody. The interaction of anti-c-jun antibody with c-jun in the AP-1 complex might change the complex conformation and facilitated the interaction of c-fos with its antibody, thereby, resulting in the appearance of the second supershifted band. Nevertheless, these data suggest that the AP-1 DNA complex is mainly composed of c-jun homodimer, whereas c-jun and c-fos heterodimer could be a minor component of the whole DNA/protein complex. It has been shown that AP-1 motif is the coverging site for a number of intracellular signaling pathways that regulate transcriptions of target genes. Previously we have shown that BCSG1 mRNA expression in breast cancer cells is regulated by oncostatin M (Liu et al., 2000) , TGF-b, EGF and TGF-a (Liu, unpublished data) . It is conceivable that some of these regulators activate BCSG1 transcription through this AP-1 motif. Studies to locate the cis-acting elements that are responsive to these factors are currently being conducted.
DNA methylation to inactivate gene transcription is one of the most important mechanisms for mammalian cells to selectively express a set of genes to maintain cell-type speci®city (Kudo and Fukuda, 1995; Griswold and Kim, 2001 ). Loss of cell-type speci®city is fundamentally related to human cancer. BCSG1 gene is abundantly expressed in brain tissue, but not in normal breast tissue, or breast tissues with benign diseases. However, this tissue speci®city is disturbed during the breast cancer disease progression, as BCSG1 gene becomes actively transcribed in neoplastic mammary epithelial cells of invasive and metastatic breast carcinomas. In this study we demonstrate that changes in the methylation status of BCSG1 in the exon 1 region play an important role in the abnormal expression of BCSG1.
By using the method of genomic bisul®te DNA sequencing, we show that in MCF-7 cells, the exon 1 region was densely and heterogeneously methylated, and the methylation intensive spots were almost identical to that detected in HepG2 cells. By contrast, the exon 1 region of BCSG1 was completely unmethylated in SKBR-3 and T47D cells. These data show a direct correlation of DNA methylation of the exon 1 and BCSG1 expression. To gain additional evidence that DNA methylation of the exon 1 inhibits BCSG1 mRNA expression in MCF-7 and HepG2 cells, we utilized the compound 5-aza-C, a demethylating agent that has been widely used as a tool to study the eect of DNA methylation on gene transcription. Our combined approach of RT ± PCR and Southern blotting clearly demonstrated a dose-and a timedependent expression of BCSG1 mRNA in 5-aza-Ctreated MCF-7 and HepG2 cells. Interestingly, the levels of BCSG1 mRNA after 5-aza-C treatment were still lower than observed in SKBR-3 cells despite the exon 1 being demethylated in all of the HepG2 and in a high proportion of MCF-7 cells (Table 3 ). These data suggest that while methylation of the exon 1 plays an important dominant role in BCSG1 transcription, MCF-7 cells were cultured in RPMI medium containing 5 mM 5-aza-C for 5 days and HepG2 cells were cultured in EMEM medium containing 5 mM 5-aza-C for 6 days. The media were changed every 24 h with fresh 5-aza-C. DNA was isolated and puri®ed. Genomic bisul®te sequencing of the exon 1 region of BCSG1 was performed as described in the Materials and methods section. Nd, not determined cellular content of transcription activators or repressors that interact with the intron 1 contribute signi®cantly to the cell type-speci®c expression of BCSG1. Since abundant AP-1 DNA binding activities were detected in all four cell lines, it is possible that RE1 present in the 5' intron 1 region has a dominant negative role in the control of BCSG1 transcription in HepG2 cells. Likewise, in MCF-7 cells, RE2 located in the 3' end of the intron 1 may have a strong inhibitory eect on BCSG1 transcription.
Treating cells with demethylating agent may have a global eect on gene transcription. It is possible that the inducing eect of 5-aza-C on BCSG1 expression in MCF-7 or HepG2 cells was partially caused by aecting the expressions of RE1 or RE2 binding proteins. However, the results of our promoter analysis conducted in untreated and 5-aza-C treated cells clearly ruled out this possibility, as luciferase activities driven by dierent BCSG1 promoter regions were not altered by 5-aza-C treatment in both cell types. These data further support the notion that the low-level expression of BCSG1 after demethylation treatment is primarily caused by demethylation of exon 1.
Aberrant DNA hypomethylation of oncogenes has been linked to the development of human cancer (Feinberg and Vogelstein, 1983; Sharrard et al., 1992; Robertson and Wole, 2000) . Our novel ®nding that BCSG1 is demethylated in breast cancer cells support the hypothesis that BCSG1 might also be a protooncogene whose expression facilitates the growth and metastasis of tumor cells. Further investigations to examine the correlation of DNA methylation of the exon 1 region and BCSG1 expression in primary normal mammary epithelial cells, noninvasive, and invasive breast cancer cell lines, and in primary breast tumors are currently being conducted. These studies will provide important information for a better understanding of the breast cancer disease development and progression.
Materials and methods

Cells and reagents
Human breast cancer cell lines SKBR-3, T47D, and MCF-7 were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS) (Summit Biotechnology, Fort Collins, CO, USA). Human hepatoma cell line HepG2 was cultured in Eagle's minimum essential medium (EMEM) supplemented with 10% FBS. Rabbit polyclonal anti-BCSG1 antibodies were generously provided by Dr Benoit I Giasson at University of Pennsylvania School of Medicine. Antibodies directed to cjun, c-fos, b-actin, and members of Sp1 family were obtained from Santa Cruz Biotechnology.
Cloning of the 5'-flanking region and intron 1 of the human BCSG1 gene Human genomic clone RP11-411A19 was obtained from the Sanger Centre (Wellcome Trust Genome Campus, Hinxton, Cambridge, UK) and was digested with restriction enzymes SacI and BamHI. The DNA fragments were separated on a 0.8% agarose gel, denatured, transferred to a nylon membrane, and UV cross-linked. A probe of 60 base single-stranded oligonucleotide corresponding to the 5' untranscribed region of the published persyn genomic sequence (141 to 200) (GenBank TM /EBI accession number AF0037207) was end-labeled with T4 polynucleotide kinase in the presence of [g-32 P]ATP. This probe was hybridized to the membrane and a single band of 1.7 kb was identi®ed. This fragment was isolated from a duplicate of the agarose gel and subcloned between the SacI and BamHI sites of pBluscript KS+ vector (Stratagene). Because intron 1 was truncated at the BamHl site, a PCR reaction was performed to isolate the 3' portion of intron 1 using the genomic clone RP11-411A19 as the template. The PCR product contains the BCSG1 gene sequence +485 to +935 and an additional HindIII site at the 3' end. This fragment was digested with BamHI and HindIII and inserted between the BamHI and HindIII sites of pBS-BCSG1759. The resulting vector pBS-BCSG2195 was sequenced in sense and antisense directions using vector-speci®c primers. In addition, six additional internal primers were designed to obtain the complete sequence. Table 1 describes the sequences of sequencing primers and other oligonucleotides used in this study.
Primer extension assay
A 24 base antisense primer, BCSG-PR2, was designed from the ®rst exon and this primer corresponds to the BCSG1 gene +9 to 715, relative to the ATG translation start codon. One microgram of poly(A) mRNA from SKBR-3 or T47D cells were annealed to 0.1 pmol of 32 P-labeled BCSG-PR2 primer. Extension was carried out using the Primer Extension Kit from Promega as previously described (Ma et al., 1999) . The product of the extension reaction and 32 P-end labeled DNA molecular markers were separated on a 6% denaturing polyacrylamide gel and visualized on a PhosphorImager.
Construction of BCSG1 promoter luciferase reporters
To construct BCSG1 promoter luciferase reporter BCSG-1249 (71260/712), site-directed mutagenesis was conducted on the template DNA pBS-BCSG1759 to introduce a HindIII site at position 712 by using the QuickChange TM Site-directed Mutagenesis Kit (Stratagene, San Diego, CA, USA). The 5' region (71260 to 712) was released by cutting with SacI and HindIII and subcloned into the promoter less ®re¯y luciferase vector pGL3-basic. To construct BCSG-1759 (71260/+499), the 1759 bp insert was isolated from pBS-BCSG1759 by cutting with SacI and EcoR1 and subcloned between the SacI and EcoR1 sites of pGL3-basic in which a sv40 acceptor splice sequence has been inserted 5' of the luciferase gene. The ATG start codon of BCSG1 at position +1 was altered by sitedirected mutation to guarantee the correct translation of luciferase gene product. The reporter BCSG-2195 (71260/ +935) was constructed by isolation of the 2195 bp insert from pBS-BCSG2195 and subcloned into pGL3-basic.
To construct additional reporters with dierent 5' or 3' deletions, site-directed mutagenesis was performed on template DNA BCSG-2195 to introduce a unique restriction enzyme cutting site at dierent locations within the BCSG promoter sequence. The desired fragment was then isolated by restriction enzyme digestion and subcloned into pGL3-basic.
The Sp1 deletion vector BCSG-1759-Sp1 del was constructed by creating BglII sites adjacent to the 5' and the 3' end of the GC-rich region of BCSG-1759. The mutated plasmid was digested with BglII; the vector with remaining promoter sequence was religated.
Note that exon 1 of BCSG1 gene is also the coding exon containing the ATG translation start codon, thus, the ATG codon at +1 position has been mutated in all the constructs except BCSG-1249 whose promoter sequence (71260 to 712) does not include the ATG site.
Transient transfection assays
SKBR-3, T47D, and MCF-7 cells cultured in 24-well plates at a density of 0.12610 6 cells per well were transiently transfected with a total of 200 ng of reporter DNA and 2 ng of pRL-SV40 (Renilla, Promega) per well mixed with the Eectin reagent (Qiagen, Valencia, CA, USA). Forty hours after transfection, luciferase activities were measured using the Promega Dual Luciferase Assay System. HepG2 cells seeded in 24-well plates were transfected by the method of calcium phosphate coprecipitation as previously described (Liu et al., 1997b) .
Western blot analysis of BCSG1 protein
The methods for isolation of cell lysate and conduction of Western blot analysis have been previously described (Liu et al., 2000) .
Electrophoresis mobility shift assays (EMSA)
Nuclear extracts were prepared as previously described (Liu et al., 1997b) . The double-stranded oligonucleotide probe was annealed and endlabeled with T4 polynucleotide kinase in the presence of [g-32 P]ATP. Each binding reaction was composed of 10 mM HEPES, pH 7.8, 2 mM MgCL 2 , 2 mM DTT, 100 mM NaCL, 10% glycerol, 2 mg of poly (dI-dC), 1 mg BSA, and 4 mg nuclear extract in a ®nal volume of 20 ml. Nuclear extracts were incubated with 1 ng of 32 P-labeled probe (40 ± 80610 3 c.p.m.) for 10 min at room temperature. The reaction mixtures were loaded onto a 6% polyacrylamide gel and run in TGE buer at 180 V for 2 ± 3 h at 48C. The gels were dried and visualized on a PhosphorImager. In competition analysis, nuclear extracts were incubated with 50 ± 100-fold molar excess of unlabeled competitor DNA for 5 min prior to the addition of the labeled probe. For supershift assays, antibody was incubated with nuclear extract for 30 ± 60 min at room temperature prior to the addition of the probe.
Genomic bisulfite DNA sequencing
Genomic DNA was isolated from cells by using a genomic isolation kit purchased from Promega. Two mg of genomic DNA from each sample was modi®ed by sodium bisul®te as described previously (Esteller et al., 2000) . The modi®ed DNA was ampli®ed with primer BCSG-S1F and BCSG-S1R. This primer set ampli®ed the modi®ed sense strand of BCSG1 gene covering the region 7342 to +260. PCR reactions were performed in a volume of 25 ml containing 16PCR buer, 1.5 mM MgCL 2 , 0.2 mM dNTP, 25 pM of each primer, and 2.5 units of platinum Taq polymerase (Gibco Life Science). PCR reactions were 948C for 1 min, and 35 cycles at 948C for 30 s, 558C for 30 s, and 728C for 30 s, and ®nally 728C for 5 min. The 600 bp PCR product was gel-puri®ed and ligated into PCR2.1 Topo cloning vector (Invitrogen, Carlsbad, CA, USA). After transformation, individual colonies were picked and the insert was PCR ampli®ed as described above and sequenced using BCSG-S2R as the primer.
5-Aza-2'-deoxycytidine treatment MCF-7 and HepG2 cells were cultured in medium containing 1 or 5 mM of 5-Aza-2'-deoxycytidine (5-aza-C) for various times and the medium and drug were replaced every 24 h.
RT ± PCR analysis of BCSG1 mRNA
Cells were lysed in Ultraspec RNA lysis solution (Biotecxs Laboratory, Houston, TX, USA) and total cellular RNA was isolated according to the vendor's protocol. RT ± PCR was conducted using Titan one tube RT ± PCR system from Roche Molecular Biochemicals (Indianapolis, IN, USA). RT reactions were performed at 508C for 30 min in a volume of 50 ml containing 1 mg of total RNA. The subsequent PCR reactions were performed in the same reaction mixture with speci®c primers for BCSG1 or GAPDH. PCR reactions with a total of 35 cycles were performed. The conditions for the ®rst 10 cycles were 948C for 10 s, 558C for 30 s, and 688C for 45 s. For the last 25 cycles, the elongation time at 688C was increased 5 s per cycle.
Abbreviations AP-1, activator protein 1; 5-aza-C, 5-Aza-2'-deoxycytidine; BCSG1, breast cancer speci®c gene 1; EMSA, electrophoresis mobility shift assay; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; OM, oncostatin M; RE1, repressive element 1; RE2, repressive element 2
